6-Trifluoromethyl-7-nitro-1,4-dihydro-2,3-quinoxalinedione | 115581-84-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-Trifluoromethyl-7-nitro-1,4-dihydro-2,3-quinoxalinedione
• 英文别名: 6-nitro-7-(trifluoromethyl)-1,4-dihydroquinoxaline-2,3-dione
• CAS: 115581-84-5
• 化学式: C₉H₄F₃N₃O₄
• 分子量: 275.144
• InChiKey: VICKEBHDWGLQEW-UHFFFAOYSA-N

物化性质

• 熔点：
  >300 °C
• 密度：
  1.650±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  6-Trifluoromethyl-7-nitro-1,4-dihydro-2,3-quinoxalinedione 在 palladium on activated charcoal 氢气 作用下， 生成 6-amino-7-trifluoromethyl-2,3(1H,4H)-quinoxalinedione
  参考文献：
  名称：

  Pyrrolylquinoxalinediones: A new class of AMPA receptor antagonists

  摘要：

  Pyrrolylquinoxalinediones were synthesized and their affinities for the AMPA receptor were determined. Most compounds showed moderate to good affinities. The acetic acid derivative 8b exhibited a K-i value of 70 nM and was equipotent to NBQX 1. Structure activity relationships are discussed. Selected compounds were tested for their potency to inhibit AMPA induced lethal convulsions in mice. In this in vivo model the compounds showed improved potency compared with NBQX. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/s0960-894x(96)00534-3
• 作为产物：
  描述：

  4-氯-3-硝基三氟甲苯 在 硫酸 、 铁粉 、 溶剂黄146 、 potassium nitrate 作用下， 生成 6-Trifluoromethyl-7-nitro-1,4-dihydro-2,3-quinoxalinedione
  参考文献：
  名称：

  Pyrrolylquinoxalinediones: A new class of AMPA receptor antagonists

  摘要：

  Pyrrolylquinoxalinediones were synthesized and their affinities for the AMPA receptor were determined. Most compounds showed moderate to good affinities. The acetic acid derivative 8b exhibited a K-i value of 70 nM and was equipotent to NBQX 1. Structure activity relationships are discussed. Selected compounds were tested for their potency to inhibit AMPA induced lethal convulsions in mice. In this in vivo model the compounds showed improved potency compared with NBQX. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/s0960-894x(96)00534-3

文献信息

• Glycine receptor antagonists and the use thereof
  申请人：The State of Oregon, acting by and through The Oregon State Board of

  公开号：US05514680A1

  公开（公告）日：1996-05-07

  Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.

  治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元损失的方法，以及治疗包括阿尔茨海默病、肌萎缩侧索硬化、亨廷顿病和唐氏综合症在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度活跃的副作用，以及治疗焦虑、慢性疼痛、癫痫、诱导麻醉和治疗精神病的方法，通过向需要此类治疗的动物施用一种对甘氨酸结合位点具有高亲和力、无PCP副作用且能穿过动物血脑屏障的化合物来进行披露。还披露了新型的1,4-二氢喹诺酮-2,3-二酮，及其药物组合物。还披露了1,4-二氢喹诺酮-2,3-二酮的高度可溶性铵盐。
• Method of screening binding of a compound to a receptor
  申请人：——

  公开号：US20030215959A1

  公开（公告）日：2003-11-20

  Disclosed is a method of measuring affinity of a test compound for a receptor protein. The method includes the steps of providing a receptor-ligand complex comprising a receptor and a quinoxaline derivative ligand bound thereto; then contacting the receptor-ligand complex with a test compound, thereby yielding a receptor-test compound complex and an amount of free quinoxaline derivative; and then measuring the amount of the free quinoxaline derivative generated as a result of the previous step. In this fashion, the affinity of the test compound for the receptor can be determined.

  本发明公开了一种测量试验化合物与受体蛋白亲和力的方法。该方法包括以下步骤：提供一个包括受体和一个喹喔啉衍生物配体结合在一起的受体-配体复合物；然后将受体-配体复合物与试验化合物接触，从而产生受体-试验化合物复合物和一定量的游离喹喔啉衍生物；然后测量由于前一步骤而产生的游离喹喔啉衍生物的数量。通过这种方法，可以确定试验化合物与受体的亲和力。
• 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical
  申请人：A/S Ferrosan

  公开号：US04812458A1

  公开（公告）日：1989-03-14

  Heterocyclic dihydroxyquinoxaline compounds having the formula ##STR1## wherein R.sup.1 is halogen, CN, CF.sub.3, ethynyl, or N.sub.3 and R.sup.2 is SO.sub.2 C.sub.1-3 -alkyl, CF.sub.3, NO.sub.2, ethynyl, or CN. The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use. The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters, particularly the quisqualate receptors, and especially as neuroleptics.

  具有以下式子的杂环二羟基喹喔啉化合物：##STR1## 其中R.sup.1是卤素、CN、CF.sub.3、乙炔或N.sub.3，R.sup.2是SO.sub.2 C.sub.1-3-烷基、CF.sub.3、NO.sub.2、乙炔或CN。本发明还涉及制备该化合物的方法、其药物组合物以及它们的用途。该化合物可用于治疗由兴奋性神经递质过度活跃引起的症状，特别是对于石竹酸受体，尤其是作为神经抑制剂。
• Quinoxaline compounds and their preparation and use
  申请人：NOVO NORDISK A/S

  公开号：EP0260467A2

  公开（公告）日：1988-03-23

  Heterocyclic dihydroxyquinoxaline compounds having the formula wherein R¹ is halogen, CN, CF₃, ethynyl, or N₃ and R² is SO₂C1-3-alkyl, CF₃, NO₂, ethynyl, or CN. The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use. The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters, particularly the quisqualate receptors, and especially as neuroleptics.

  具有以下式子的杂环二羟基喹喔啉化合物 其中 R¹ 是卤素、CN、CF₃、乙炔基或 N₃ 和 R² 是 SO₂C1-3-烷基、CF₃、NO₂、乙炔基或 CN。 本发明还涉及化合物的制备方法、其药物组合物及其用途。 本发明的化合物可用于治疗兴奋性神经递质，特别是喹乙醇受体活性亢进引起的症状，尤其可用作神经抑制剂。
• HONORE, TAGE;DREJER, JZHUSTORGEN;JASOVSEN, POUL;NIELSEN, FLEMMING E.
  作者：HONORE, TAGE、DREJER, JZHUSTORGEN、JASOVSEN, POUL、NIELSEN, FLEMMING E.

  DOI：——

  日期：——